- Home
- EVT vs HRMY Comparison
EVT vs HRMY Comparison
Compare EVT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- HRMY
- Stock Information
- Founded
- EVT 2003
- HRMY 2017
- Country
- EVT United States
- HRMY United States
- Employees
- EVT N/A
- HRMY N/A
- Industry
- EVT Finance Companies
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- EVT Finance
- HRMY Health Care
- Exchange
- EVT Nasdaq
- HRMY Nasdaq
- Market Cap
- EVT 1.8B
- HRMY 1.9B
- IPO Year
- EVT N/A
- HRMY 2020
- Fundamental
- Price
- EVT $24.60
- HRMY $33.63
- Analyst Decision
- EVT
- HRMY Buy
- Analyst Count
- EVT 0
- HRMY 10
- Target Price
- EVT N/A
- HRMY $49.80
- AVG Volume (30 Days)
- EVT 121.5K
- HRMY 431.7K
- Earning Date
- EVT 01-01-0001
- HRMY 10-29-2024
- Dividend Yield
- EVT 7.72%
- HRMY N/A
- EPS Growth
- EVT N/A
- HRMY N/A
- EPS
- EVT N/A
- HRMY 2.11
- Revenue
- EVT N/A
- HRMY $681,879,000.00
- Revenue This Year
- EVT N/A
- HRMY $24.79
- Revenue Next Year
- EVT N/A
- HRMY $17.98
- P/E Ratio
- EVT N/A
- HRMY $15.70
- Revenue Growth
- EVT N/A
- HRMY 25.83
- 52 Week Low
- EVT $18.70
- HRMY $28.14
- 52 Week High
- EVT $23.82
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- EVT 36.30
- HRMY 49.27
- Support Level
- EVT $24.56
- HRMY $31.50
- Resistance Level
- EVT $25.62
- HRMY $35.99
- Average True Range (ATR)
- EVT 0.24
- HRMY 1.18
- MACD
- EVT -0.12
- HRMY -0.06
- Stochastic Oscillator
- EVT 7.52
- HRMY 47.44
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.